HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aloe Farms' Claims, GMP Practices Rub FDA The Wrong Way

This article was originally published in The Rose Sheet

Executive Summary

The firm's violative label claims include Aloe Vera Gel "cures everything" and its branding mistakes include failing to list all ingredients for its Aloe Capsules and Original Whole Leaf Aloe Vera Capsules.

You may also be interested in...



Aloe Supplement Makes Drug Claims, Touts HHS 'Certificate' Of Approval

The FDA ORA Chicago District's lengthy inspection at a Illinois firm in May, June and July 2015 and a review of its website found drug claims including "helps control diabetes."

FDA Warning Letter Depicts Personal-Care Regulation's Present, Possible Future

Cosmetic firms already are being closely watched by FDA for overreaching product claims, but if formal good manufacturing practices are established for the sector down the road under regulatory reform legislation, companies could be targeted increasingly with warning letters like that issued to Beauty & Health International for quality-control violations at its Garden Grove, California facility.

FDA Looks To Hone Supplement GMP Compliance With Sharper Focus For Inspections

FDA's supplement programs office is increasing its outreach to work with other agencies, states, the industry, health care professionals and consumer groups to improve oversight of the industry. The agency also expects GMP inspections to improve with officials focused on certain product categories.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS108522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel